Anti-GM-CSF 抗体 [EPR25991-223] (ab300495)
![Western blot - Anti-GM-CSF antibody [EPR25991-223] (ab300495)](https://www.abcam.co.jp/ps/products/300/ab300495/Images/AB300495-486144-anti-CSF2-antibody-epr25991-223-western-blot.jpg "Western blot - Anti-GM-CSF antibody [EPR25991-223] (ab300495)")
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR25991-223] to GM-CSF
- Suitable for: WB, IP
- Reacts with: Human
Related conjugates and formulations
製品の概要
-
製品名
Anti-GM-CSF antibody [EPR25991-223]
GM-CSF 一次抗体 製品一覧 -
製品の詳細
Rabbit monoclonal [EPR25991-223] to GM-CSF -
由来種
Rabbit -
アプリケーション
適用あり: WB, IPmore details
適用なし: ICC/IF,IHC-Fr or IHC-P -
種交差性
交差種: Human
非交差種: Mouse, Rat -
免疫原
Recombinant fragment. This information is proprietary to Abcam and/or its suppliers.
-
ポジティブ･コントロール
- WB: HuT-78 and Jurkat treated with 80nM TPA and 30µM ionomycin for 5 hours, then with 300ng/ml BFA added for 4 hours whole cell lysate. IP: HuT-78 treated with 80nM TPA and 30µM ionomycin for 5 hours, then with 300ng/ml BFA added for 4 hours cell lysates.
-
特記事項
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
製品の特性
-
製品の状態
Liquid -
保存方法
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
バッファー
pH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA -
Concentration information loading... -
精製度
Protein A purified -
ポリ/モノ
モノクローナル -
クローン名
EPR25991-223 -
アイソタイプ
IgG -
研究分野
関連製品
-
Alternative Versions
-
Compatible Secondaries
-
Isotype control
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab300495の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
| アプリケーション | Abreviews | 特記事項 |
|---|---|---|
| WB |
1/1000. Predicted molecular weight: 16 kDa.
|
|
| IP |
1/30.
|
| 特記事項 |
|---|
|
WB
1/1000. Predicted molecular weight: 16 kDa. |
|
IP
1/30. |
ターゲット情報
-
機能
Cytokine that stimulates the growth and differentiation of hematopoietic precursor cells from various lineages, including granulocytes, macrophages, eosinophils and erythrocytes. -
配列類似性
Belongs to the GM-CSF family. -
細胞内局在
Secreted. - Information by UniProt
-
参照データベース
- Entrez Gene: 1437 Human
- Omim: 138960 Human
- SwissProt: P04141 Human
- Unigene: 1349 Human
-
別名
- Colony stimulating factor 2 (granulocyte-macrophage) antibody
- Colony Stimulating Factor 2 antibody
- Colony stimulating factor antibody
see all
画像
-
Western blot - Anti-GM-CSF antibody [EPR25991-223] (ab300495)All lanes : Anti-GM-CSF antibody [EPR25991-223] (ab300495) at 1/1000 dilution
Lane 1 : Untreated HuT-78 (human Sezary syndrome cutaneous T lymphocyte) whole cell lysate
Lane 2 : HuT-78 treated with 80nM TPA and 30µM ionomycin for 5 hours, then with 300ng/ml BFA added for 4 hours whole cell lysate
Lane 3 : Untreated Jurkat (human T cell leukemia T lymphocyte) whole cell lysate
Lane 4 : Jurkat treated with 80nM TPA and 30µM ionomycin for 5 hours, then with 300ng/ml BFA added for 4 hours whole cell lysate
Lysates/proteins at 20 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution
Predicted band size: 16 kDa
Observed band size: 15,18,22 kDa why is the actual band size different from the predicted?The expression profile/ molecular weight observed is consistent with what has been described in the literature (PMID: 14512323).
Blocking and dilution buffer and concentration: 5% NFDM/TBST.
Exposure time: Lane 1-2: 15 seconds
Lane 3-4: 37 seconds -
![Immunoprecipitation - Anti-GM-CSF antibody [EPR25991-223] (ab300495)](https://www.abcam.co.jp/ps/products/300/ab300495/Images/AB300495-486145-anti-CSF2-antibody-epr25991-223-immunoprecipitation.jpg)
Immunoprecipitation - Anti-GM-CSF antibody [EPR25991-223] (ab300495)GM-CSF was immunoprecipitated from 10 µg of HuT-78 (human Sezary syndrome cutaneous T lymphocyte) treated with 80nM TPA and 30μM ionomycin for 5 hours, then with 300ng/ml BFA added for 4 hours whole cell lysate with ab300495 at 1/30 dilution. VeriBlot for IP secondary antibody(HRP) (ab131366) at 1/5000 dilution was used as a secondary antibody.
Lane 1: HuT-78 (human Sezary syndrome cutaneous T lymphocyte) treated with 80nM TPA and 30μM ionomycin for 5 hours, then with 300ng/ml BFA added for 4 hours whole cell lysate 10 µg (Input).
Lane2: ab300495 IP in HuT-78 treated with 80nM TPA and 30μM ionomycin for 5 hours, then with 300ng/ml BFA added for 4 hours cell lysates.
Lane 3: Rabbit monoclonal IgG (ab172730) instead of ab300495 in HuT-78 treated with 80nM TPA and 30μM ionomycin for 5 hours, then with 300ng/ml BFA added for 4 hours cell lysates.
Blocking and dilution buffer and concentration: 5% NFDM/TBST.
Exsposure time: 75 seconds.
The expression profile/ molecular weight observed is consistent with what has been described in the literature (PMID: 14512323).
-
![Anti-GM-CSF antibody [EPR25991-223] (ab300495)](https://www.abcam.co.jp/ps/products/300/ab300495/Images/AB300495-3-benefitsofrecombinantantibodies.jpg)
Anti-GM-CSF antibody [EPR25991-223] (ab300495)
プロトコール
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
データシートおよび資料
-
SDS download
-
Datasheet download
Certificate of Compliance
参考文献 (2)
ab300495 は 2 報の論文で使用されています。
- Li CF et al. PAK1 overexpression promotes myxofibrosarcoma angiogenesis through STAT5B-mediated CSF2 transactivation: clinical and therapeutic relevance of amplification and nuclear entry. Int J Biol Sci 19:3920-3936 (2023). PubMed: 37564209
- Filin IY et al. T-Lymphocytes Activated by Dendritic Cells Loaded by Tumor-Derived Vesicles Decrease Viability of Melanoma Cells In Vitro. Curr Issues Mol Biol 45:7827-7841 (2023). PubMed: 37886937